Compass Inc. Class A Common Stock vs Quest Diagnostics Inc — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while Quest Diagnostics Inc trades at $230.72 (market cap $25.06B). The key difference: Quest Diagnostics Inc is far larger — about 3.6× Compass Inc. Class A Common Stock's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Compass Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Quest Diagnostics Inc for 56 Days on average.
| COMP | DGX | |
|---|---|---|
Market Cap | $7.05B | $25.06B |
Volume | 15,310,192 | 927,361 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $247.45 |
52-Week Low | $6.68 | $173.49 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $10.47B | $30.82B |
Dividend Yield | — | 1.52% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →